1
|
White MJ, Cheatham L, Wen S, Scarfe G, Cidado J, Reimer C, Hariparsad N, Jones RDO, Drew L, McGinnity DF, Vasalou C. A PKPD Case Study: Achieving Clinically Relevant Exposures of AZD5991 in Oncology Mouse Models. AAPS J 2023; 25:66. [PMID: 37380821 DOI: 10.1208/s12248-023-00836-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Accepted: 06/13/2023] [Indexed: 06/30/2023] Open
Abstract
Capturing human equivalent drug exposures preclinically is a key challenge in the translational process. Motivated by the need to recapitulate the pharmacokinetic (PK) profile of the clinical stage Mcl-1 inhibitor AZD5991 in mice, we describe the methodology used to develop a refined mathematical model relating clinically relevant concentration profiles to efficacy. Administration routes were explored to achieve target exposures matching the clinical exposure of AZD5991. Intravenous infusion using vascular access button (VAB) technology was found to best reproduce clinical target exposures of AZD5991 in mice. Exposure-efficacy relationships were evaluated, demonstrating that dissimilar PK profiles result in differences in target engagement and efficacy outcomes. Thus, these data underscore the importance of accurately ascribing key PK metrics in the translational process to enable clinically meaningful predictions of efficacy.
Collapse
Affiliation(s)
- Michael J White
- AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA.
| | - Letitia Cheatham
- AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA
| | - Shenghua Wen
- AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA
| | - Graeme Scarfe
- AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA
| | - Justin Cidado
- AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA
| | - Corinne Reimer
- AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA
| | - Niresh Hariparsad
- AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA
| | - Rhys D O Jones
- AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA
| | - Lisa Drew
- AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA
| | - Dermot F McGinnity
- AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA
| | - Christina Vasalou
- AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA
| |
Collapse
|
2
|
Shaz B, Kraft B, Troy J, Poehlein E, Chen L, Cheatham L, Manyara R, Hanafy K, Brown L, Scott M, Palumbo R, Vrionis F, Kurtzberg J. Mesenchymal Stem/Stromal Cells: SAFETY OF CORD TISSUE DERIVED MESENCHYMAL STROMAL CELLS IN COVID-19 RELATED ACUTE RESPIRATORY DISTRESS SYNDROME. Cytotherapy 2022. [PMCID: PMC9035758 DOI: 10.1016/s1465-3249(22)00181-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
3
|
Ressler B, Noldner P, Meadows N, Rudisill A, Cheatham L, Waters-Pick B, Dawson G, Sun J, Kurtzberg J. Meeting the demands of msc production for clinical studies. Cytotherapy 2019. [DOI: 10.1016/j.jcyt.2019.03.496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
4
|
Wagoner MP, Yang Y, McDuffie JE, Klapczynski M, Buck W, Cheatham L, Eisinger D, Sace F, Lynch KM, Sonee M, Ma JY, Chen Y, Marshall K, Damour M, Stephen L, Dragan YP, Fikes J, Snook S, Kinter LB. Evaluation of Temporal Changes in Urine-based Metabolomic and Kidney Injury Markers to Detect Compound Induced Acute Kidney Tubular Toxicity in Beagle Dogs. Curr Top Med Chem 2017; 17:2767-2780. [PMID: 28714420 DOI: 10.2174/1568026617666170713172331] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2016] [Revised: 04/06/2017] [Accepted: 04/19/2017] [Indexed: 11/22/2022]
Abstract
Urinary protein biomarkers and metabolomic markers have been leveraged to detect acute Drug Induced Kidney Injury (DIKI) in rats; however, the utility of these indicators to enable early detection of DIKI in canine models has not been well documented. Therefore, we evaluated temporal changes in biomarkers and metabolites in urine from male and female beagle dogs. Gentamicin- induced kidney lesions in male dogs were characterized by moderate to severe tubular epithelial cell degeneration/necrosis, epithelial cell regeneration and dilation; and a unique urinebased metabolomic fingerprint. These metabolite changes included time and treatment-dependent increases in lactate, taurine, glucose, lactate, alanine, and citrate as well as 9 other known metabolites. As early as 3 days post dose, gentamicin induced increases in urinary albumin, clusterin, neutrophil gelatinase associated protein (NGAL) and total protein concentrations. Urinary albumin, clusterin, and NGAL showed earlier and more robust elevations than traditional kidney safety biomarkers, blood urea nitrogen and serum creatinine. Elevations in urinary kidney injury molecule 1 (KIM-1) were less reliable for detection of gentamicin nephrotoxicity in dogs based on values generated utilizing multiple first-generation, canine-specific KIM-1 immunoassays. The metabolic fingerprint was further evaluated in male and female dogs that received Compound A which induced slightly reversible renal tubular alterations characterized as degeneration/necrosis and concurrent significant increases in urinary taurine amongst other markers. These data support further investigations to demonstrate the value of urinary metabolites, albumin, clusterin, NGAL and taurine as promising markers to enable early detection of DIKI in dogs.
Collapse
Affiliation(s)
- M P Wagoner
- Takeda Pharmaceuticals, 35 Landsdowne St., Cambridge, MA, 02139. United States
| | - Y Yang
- Abbvie, North Chicago, IL. United States
| | - J E McDuffie
- Janssen Research & Development, La Jolla, CA. United States
| | | | - W Buck
- Abbvie, North Chicago, IL. United States
| | - L Cheatham
- AstraZeneca Pharmaceuticals, Waltham, MA, USA; 2Abbvie, North Chicago, IL. United States
| | | | - F Sace
- Biogen Idec, Waltham, MA. United States
| | - K M Lynch
- Abbvie, North Chicago, IL. United States
| | - M Sonee
- Janssen Research & Development, La Jolla, CA. United States
| | - J-Y Ma
- Janssen Research & Development, La Jolla, CA. United States
| | - Y Chen
- Janssen Research & Development, La Jolla, CA. United States
| | - K Marshall
- Janssen Research & Development, La Jolla, CA. United States
| | - M Damour
- Janssen Research & Development, La Jolla, CA. United States
| | - L Stephen
- Janssen Research & Development, La Jolla, CA. United States
| | | | - J Fikes
- Myriad RBM, TX. United States
| | - S Snook
- Janssen Research & Development, La Jolla, CA. United States
| | - L B Kinter
- Pfizer, Inc., New York City, NC. United States
| |
Collapse
|
5
|
Storms R, Lillich M, Parrott R, Noldner P, Meadows N, Cheatham L, Kurtzberg J. Characterization of msc derived from umbilical cord tissues. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.280] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
6
|
Muñiz Alers S, Page K, Simmons R, Waters-Pick B, Cheatham L, Troy J, Kurtzberg J. Automated thawing increases recovery of colony forming units from banked cord blood unit graft. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
7
|
Keirstead ND, Wagoner MP, Bentley P, Blais M, Brown C, Cheatham L, Ciaccio P, Dragan Y, Ferguson D, Fikes J, Galvin M, Gupta A, Hale M, Johnson N, Luo W, McGrath F, Pietras M, Price S, Sathe AG, Sasaki JC, Snow D, Walsky RL, Kern G. Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers. Toxicol Sci 2013; 137:278-91. [PMID: 24189134 DOI: 10.1093/toxsci/kft247] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Despite six decades of clinical experience with the polymyxin class of antibiotics, their dose-limiting nephrotoxicity remains difficult to predict due to a paucity of sensitive biomarkers. Here, we evaluate the performance of standard of care and next-generation biomarkers of renal injury in the detection and monitoring of polymyxin-induced acute kidney injury in male Han Wistar rats using colistin (polymyxin E) and a polymyxin B (PMB) derivative with reduced nephrotoxicity, PMB nonapeptide (PMBN). This study provides the first histopathological and biomarker analysis of PMBN, an important test of the hypothesis that fatty acid modifications and charge reductions in polymyxins can reduce their nephrotoxicity. The results indicate that alterations in a panel of urinary kidney injury biomarkers can be used to monitor histopathological injury, with Kim-1 and α-GST emerging as the most sensitive biomarkers outperforming clinical standards of care, serum or plasma creatinine and blood urea nitrogen. To enable the prediction of polymyxin-induced nephrotoxicity, an in vitro cytotoxicity assay was employed using human proximal tubule epithelial cells (HK-2). Cytotoxicity data in these HK-2 cells correlated with the renal toxicity detected via safety biomarker data and histopathological evaluation, suggesting that in vitro and in vivo methods can be incorporated within a screening cascade to prioritize polymyxin class analogs with more favorable renal toxicity profiles.
Collapse
|
8
|
Brott DA, Diamond M, Campbell P, Zuvich A, Cheatham L, Bentley P, Gorko MA, Fikes J, Saye J. An acute rat in vivo screening model to predict compounds that alter blood glucose and/or insulin regulation. J Pharmacol Toxicol Methods 2013; 68:190-196. [PMID: 23835094 DOI: 10.1016/j.vascn.2013.06.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2013] [Revised: 05/29/2013] [Accepted: 06/28/2013] [Indexed: 01/26/2023]
Abstract
INTRODUCTION Drug-induced glucose dysregulation and insulin resistance have been associated with weight gain and potential induction and/or exacerbation of diabetes mellitus in the clinic suggesting they may be safety biomarkers when developing antipsychotics. Glucose and insulin have also been suggested as potential efficacy biomarkers for some oncology compounds. The objective of this study was to qualify a medium throughput rat in vivo acute Intravenous Glucose Tolerance Test (IVGTT) for predicting compounds that will induce altered blood glucose and/or insulin levels. METHODS Acute and sub-chronic studies were performed to qualify an acute IVGTT model. Double cannulated male rats (Han-Wistar and Sprague-Dawley) were administered vehicle, olanzapine, aripiprazole or other compounds at t=-44min for acute studies and at time=-44min on the last day of dosing for sub-chronic studies, treated with dextrose (time=0min; i.v.) and blood collected using an automated Culex® system for glucose and insulin analysis (time=-45, -1, 2, 10, 15, 30, 45, 60, 75, 90, 120, 150 and 180min). RESULTS Olanzapine significantly increased glucose and insulin area under the curve (AUC) values while aripiprazole AUC values were similar to control, in both acute and sub-chronic studies. All atypical antipsychotics evaluated were consistent with literature references of clinical weight gain. As efficacy biomarkers, insulin AUC but not glucose AUC values were increased with a compound known to have insulin growth factor-1 (IGF-1) activity, compared to control treatment. DISCUSSION These studies qualified the medium throughput acute IVGTT model to more quickly screen compounds for 1) safety - the potential to elicit glucose dysregulation and/or insulin resistance and 2) efficacy - as a surrogate for compounds affecting the glucose and/or insulin regulatory pathways. These data demonstrate that the same in vivo rat model and assays can be used to predict both clinical safety and efficacy of compounds.
Collapse
Affiliation(s)
- David A Brott
- Global Safety Assessment, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850 USA.
| | - Melody Diamond
- Global Safety Assessment, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850 USA
| | - Pam Campbell
- Global Safety Assessment, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850 USA
| | - Andy Zuvich
- Global Safety Assessment, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850 USA
| | - Letitia Cheatham
- Global Safety Assessment, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850 USA
| | - Patricia Bentley
- Global Safety Assessment, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850 USA
| | - Mary Ann Gorko
- Global Safety Assessment, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850 USA
| | - James Fikes
- Global Safety Assessment, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850 USA
| | - JoAnne Saye
- Global Safety Assessment, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19850 USA
| |
Collapse
|
9
|
Northrup R, Kuroda K, Duus EM, Barnes SR, Cheatham L, Wiley T, Pietra C. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Support Care Cancer 2013; 21:2409-15. [PMID: 23579947 PMCID: PMC3728440 DOI: 10.1007/s00520-013-1800-0] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2012] [Accepted: 03/25/2013] [Indexed: 01/06/2023]
Abstract
Purpose Anamorelin (ONO-7643) is an orally active ghrelin receptor agonist in development for non-small cell lung cancer (NSCLC)-related anorexia/cachexia. It displays both orexigenic and anabolic properties via ghrelin mimetic activity and transient increases in growth hormone (GH). However, increasing GH and insulin-like growth factor-1 in cancer patients raises concerns of potentially stimulating tumor growth. Therefore, we investigated the effect of ghrelin and anamorelin on tumor growth in a murine NSCLC xenograft model. Methods Female nude mice (15–21/group) with established A549 tumors were administered ghrelin (2 mg/kg i.p.), anamorelin (3, 10, or 30 mg/kg p.o.), or vehicle controls daily for 28 days. Tumor growth, food consumption, and body weight were monitored. Murine growth hormone (mGH) and murine insulin-like growth factor-1 (mIGF-1) were measured in plasma. Results Tumor growth progressed throughout the study, with no significant differences between treatment groups. Daily food consumption was also relatively unchanged, while the percentage of mean body weight gain at the end of treatment was significantly increased in animals administered 10 and 30 mg/kg compared with controls (p < 0.01). Peak mGH levels were significantly higher in ghrelin- and anamorelin-treated animals than in controls, while peak mIGF-1 levels were slightly elevated but not statistically significant. All regimens were well tolerated. Conclusions These findings demonstrate that neither anamorelin nor ghrelin promoted tumor growth in this model, despite increased levels of mGH and a trend of increased mIGF-1. Together with anamorelin’s ability to increase body weight, these results support the clinical development of ghrelin receptor agonist treatments for managing NSCLC-related anorexia/cachexia.
Collapse
Affiliation(s)
- R Northrup
- Research and Development, Helsinn Therapeutics (US), Inc., Bridgewater, NJ 08807, USA.
| | | | | | | | | | | | | |
Collapse
|
10
|
Brott DA, Bentley P, Nadella MVP, Thurman D, Fikes J, Cheatham L, McGrath F, Luo W, Kinter LB. Renal biomarker changes associated with hyaline droplet nephropathy in rats are time and potentially compound dependent. Toxicology 2012; 303:133-8. [PMID: 23159986 DOI: 10.1016/j.tox.2012.11.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2012] [Revised: 11/01/2012] [Accepted: 11/05/2012] [Indexed: 11/19/2022]
Abstract
Alpha 2u-globulin mediated hyaline droplet nephropathy (HDN) is a male rat specific lesion induced when a compound or metabolite binds to alpha 2u-globulin. The objective of this study was to investigate if the newer and more sensitive renal biomarkers would be altered with HDN as well as be able to distinguish between HDN and oxidative stress-induced kidney injury. Rats were dosed orally for 7 days to determine (1) if HDN (induced by 2-propanol or D-limonene) altered the newer renal biomarkers and not BUN or creatinine, (2) if renal biomarkers could distinguish between HDN and oxidative stress-induced kidney injury (induced by potassium bromate), (3) sensitivity of HDN-induced renal biomarker changes relative to D-limonene dose, and (4) reversibility of HDN and renal biomarkers, using vehicle or 300 mg/kg/day D-limonene with 7 days of dosing and necropsies scheduled over the period of Days 8-85. HDN-induced renal biomarker changes in male rats were potentially compound specific: (1) 2-propanol induced mild HDN without increased renal biomarkers, (2) potassium bromate induced moderate HDN with increased clusterin, and (3) D-limonene induced marked HDN with increased αGST, μGST and albumin. Administration of potassium bromate did not result in oxidative stress-induced kidney injury, based on histopathology and renal biomarkers creatinine and BUN. The compound D-limonene induced a dose dependent increase in HDN severity and renal biomarker changes without altering BUN, creatinine or NAG: (1) minimal induction of HDN and no altered biomarkers at 10 mg/kg/day, (2) mild induction of HDN with increased αGST and μGST at 50 mg/kg/day and (3) marked induction of HDN with increased αGST, μGST and albumin at 300 mg/kg/day. HDN induced by D-limonene was reversible, but with a variable renal biomarker pattern over time: Day 8 there was increased αGST, μGST and albumin; on Day 15 increased clusterin, albumin and Kim-1. In summary, HDN altered the newer and more sensitive renal biomarkers in a time and possibly compound dependent manner.
Collapse
Affiliation(s)
- David A Brott
- Global Safety Assessment, AstraZeneca Pharmaceuticals, Wilmington, DE 19850, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Abstract
PURPOSE Retrieval of an optional inferior vena cava (IVC) filter with retained thrombus may result in pulmonary emboli if the trapped thrombus is not removed along with the filter. An in vitro model was developed to determine the fate of trapped thrombus during filter removal. MATERIALS AND METHODS An in vitro IVC flow model was created with 25-mm inner diameter tubing and a 50% glycerol/water solution. Three different optional filters-Recovery (Bard, Tempe, AZ), Günther-Tulip (Cook Inc., Bloomington IN), and OptEase (Cordis Endovascular/Johnson & Johnson, Warren, NJ)-were evaluated in the study. A known mass of mature thrombus (porcine, aged 1 wk) was trapped within the optional filters. The filters were then retrieved according to the manufacturers' protocol, and the mass of thrombus recovered with the filter was determined. For each filter, five iterations were performed with initial thrombus sizes less than 1 g (group A) and an additional five iterations with initial thrombus sizes greater than 1 g (group B). RESULTS Thrombi from group A were statistically significantly smaller than those from group B (P < .0001). Retrieval of the Recovery filter resulted in an average of 25% (range, 0%-53%) and 4% (range, 0%-7%) of the clot being removed in group A and group B, respectively. Retrieval of the Günther-Tulip filter resulted in an average of 22% (group A) and 13% (group B) of the clot being removed. Retrieval of the OptEase filter resulted in an average of 43% (group A) and 0% (group B) of the clot being removed. CONCLUSIONS In our in vitro model, we have established that the mass of thrombus retrieved with optional filters is only a fraction of the initial clot burden. Because of the risk of pulmonary emboli, care should be taken when IVC filters with large amounts of trapped thrombus are removed from patients.
Collapse
Affiliation(s)
- Kenneth J Kolbeck
- Division of Interventional Radiology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
| | | | | | | |
Collapse
|
12
|
Mendoza J, Dickson J, Popa-Burke I, Mohney R, Murray J, Toole C, Cheatham L, Bernasconi P, Williams K, Hodge N. 106 A highly efficient approach to the anticancer drug discovery of potent small molecule kinase inhibitors. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80114-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
13
|
Grammer TC, Cheatham L, Chou MM, Blenis J. The p70S6K signalling pathway: a novel signalling system involved in growth regulation. Cancer Surv 1996; 27:271-292. [PMID: 8909805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
This chapter has outlined our current understanding of the regulation of p70S6K activity and its importance for cell growth and proliferation. Although incomplete at the moment, the picture of P70S6K activation reveals novel mechanisms for mitogenic signalling that closely link lipid phosphorylation and protein activation in ways previously unrecognized. Knowledge about the regulation of this signalling pathway is already proving crucial for the medical management of patients. The p70S6K regulating pathways appear to be involved in cell transformation by the polyomavirus. Rapamycin is a strong candidate for use as an immunosuppressant and is currently being tested in clinical trials. Analysis of the activation of the proto-oncogene, akt, demonstrates a possible link of the p70S6K activating pathway to carcinogenesis. Equally exciting is the recent connection between the p70S6K regulating system and IGF2 expression, which may prove crucial for the treatment of IGF2 secreting rhabdomyosarcomas. Certainly, future work will fill in the gaps in our understanding and most likely provide more surprises in the fields of cell biology and molecular oncology.
Collapse
Affiliation(s)
- T C Grammer
- Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
| | | | | | | |
Collapse
|
14
|
Abstract
The pp70/85-kDa S6 kinases, collectively referred to as pp70S6k, are thought to participate in transit through the G1 phase of the cell cycle. pp70S6k regulates the phosphorylation of the 40S ribosomal protein S6 and the transcription factor CREM tau. pp70S6k is regulated by serine/threonine phosphorylation, and although 1-phosphatidylinositol 3-kinase and phospholipase C have been implicated as upstream regulators, the mechanism of activation and identity of the upstream pp70S6k kinases remain unknown. To improve our understanding of how this mitogen-stimulated protein kinase is regulated by growth factors and the immunosuppressant rapamycin, we have initiated a structure/function analysis of pp70S6k. Our results indicate that both the N and C termini participate in the complex regulation of pp70S6k activity.
Collapse
Affiliation(s)
- L Cheatham
- Department of Cell Biology, Harvard Medical School, Boston, MA 02130, USA
| | | | | | | |
Collapse
|
15
|
Monfar M, Lemon KP, Grammer TC, Cheatham L, Chung J, Vlahos CJ, Blenis J. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. Mol Cell Biol 1995; 15:326-37. [PMID: 7528328 PMCID: PMC231963 DOI: 10.1128/mcb.15.1.326] [Citation(s) in RCA: 141] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Activation of phosphatidylinositol 3-kinase (PI3K) and activation of the 70/85-kDa S6 protein kinases (alpha II and alpha I isoforms, referred to collectively as pp70S6k) have been independently linked to the regulation of cell proliferation. We demonstrate that these kinases lie on the same signalling pathway and that PI3K mediates the activation of pp70 by the cytokine interleukin-2 (IL-2). We also show that the activation of pp70S6k can be blocked at different points along the signalling pathway by using specific inhibitors of T-cell proliferation. Inhibition of PI3K activity with structurally unrelated but highly specific PI3K inhibitors (wortmannin or LY294002) results in inhibition of IL-2-dependent but not phorbol ester (conventional protein kinase C [cPKC])-dependent pp70S6k activation. The T-cell immunosuppressant rapamycin potently antagonizes IL-2-(PI3K)- and phorbol ester (cPKC)-mediated activation of pp70S6k. Thus, wortmannin and rapamycin antagonize IL-2-mediated activation of pp70S6k at distinct points along the PI3K-regulated signalling pathway, or rapamycin antagonizes another pathway required for pp70S6k activity. Agents that raise the concentration of intracellular cyclic AMP (cAMP) and activate cAMP-dependent protein kinase (PKA) also inhibit IL-2-dependent activation of pp70S6k. In this case, inhibition appears to occur at least two points in this signalling path. Like rapamycin, PKA appears to act downstream of cPKC-mediated pp70S6k activation, and like wortmannin, PKA antagonizes IL-2-dependent activation of PI3K. The results with rapamycin and wortmannin are of added interest since the yeast and mammalian rapamycin targets resemble PI3K in the catalytic domain.
Collapse
Affiliation(s)
- M Monfar
- Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115
| | | | | | | | | | | | | |
Collapse
|
16
|
Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol 1994; 14:4902-11. [PMID: 8007986 PMCID: PMC358862 DOI: 10.1128/mcb.14.7.4902-4911.1994] [Citation(s) in RCA: 210] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Phosphatidylinositol 3-kinase (PI 3-kinase) is stimulated by insulin and a variety of growth factors, but its exact role in signal transduction remains unclear. We have used a novel, highly specific inhibitor of PT 3-kinase to dissect the role of this enzyme in insulin action. Treatment of intact 3T3-L1 adipocytes with LY294002 produced a dose-dependent inhibition of insulin-stimulated PI 3-kinase (50% inhibitory concentration, 6 microM) with > 95% reduction in the levels of phosphatidylinositol-3,4,5-trisphosphate without changes in the levels of phosphatidylinositol-4-monophosphate or its derivatives. In parallel, there was a complete inhibition of insulin-stimulated phosphorylation and activation of pp70 S6 kinase. Inhibition of PI 3-kinase also effectively blocked insulin- and serum-stimulated DNA synthesis and insulin-stimulated glucose uptake by inhibiting translocation of GLUT 4 glucose transporters to the plasma membrane. By contrast, LY294002 had no effect on insulin stimulation of mitogen-activated protein kinase or pp90 S6 kinase. Thus, activation of PI 3-kinase plays a critical role in mammalian cells and is required for activation of pp70 S6 kinase and DNA synthesis and certain forms of intracellular vesicular trafficking but not mitogen-activated protein kinase or pp90 S6 kinase activation. These data suggest that PI 3-kinase is not only an important component but also a point of divergence in the insulin signaling network.
Collapse
Affiliation(s)
- B Cheatham
- Joslin Diabetes Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215
| | | | | | | | | | | |
Collapse
|
17
|
Abstract
A frequency-multiplexed coherent optical processor is described that can compute the intensity moments of a gray-scale input image. The space-bandwidth product and dynamic range of the system's components are discussed. A major feature of the system is the ability to operate easily on its outputs to obtain bipolar moments and to correct for various component errors, nonlinearities, and nonuniformities.
Collapse
Affiliation(s)
- D Casasent
- Carnegie-Mellon University, Department of Electrical Engineering, Pittsburgh, Pennsylvania 15213, USA
| | | | | |
Collapse
|